Welcome to Idorsia

Idorsia announces financial results for the first half 2023

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

06 Sep 2023	Idorsia reacquires the world-wide rights to aprocitentan
25 Jul 2023	Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value
21 Jul 2023	Idorsia announces a cost reduction initiative to be implemented by the end of 2023

Event	When
Nine-Months 2023 Financial Results reporting*	October 24, 2023
Full-Year 2023 Financial Results reporting*	February 6, 2024
First Quarter 2024 Financial Results reporting*	April 25, 2024

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 15:41:08 CET

2.50 CHF

-0.09 (-3.63 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland